Journal of Pathology and Translational Medicine

Anne Jennifer Prabhu

2 Articles

Special AT-rich sequence-binding protein 2 (SATB2) in the differential diagnosis of osteogenic and non-osteogenic bone and soft tissue tumors: Sharon Milton, Anne Jennifer Prabhu, V. T. K. Titus, Rikki John, Selvamani Backianathan, Vrisha Madhuri; J Pathol Transl Med. 2022;56(5):270-280. Published online September 13, 2022; DOI: https://doi.org/10.4132/jptm.2022.07.11

2,030 View
80 Download
1 Web of Science
1 Crossref

Background
The diagnosis of osteosarcoma (OSA) depends on clinicopathological and radiological correlation. A biopsy is considered the gold standard for OSA diagnosis. However, since OSA is a great histological mimicker, diagnostic challenges exist. Immunohistochemistry (IHC) can serve as an adjunct for the histological diagnosis of OSA. Special AT-rich sequence-binding protein 2 (SATB2) was recently described as a reliable adjunct immunohistochemical marker for the diagnosis of OSA.
Methods
We investigated the IHC expression of SATB2 in 95 OSA and 100 non-osteogenic bone and soft tissue tumors using a monoclonal antibody (clone EPNCIR30A). The diagnostic utility of SATB2 and correlation with clinicopathological parameters were analyzed.
Results
SATB2 IHC was positive in 88 out of 95 cases (92.6%) of OSA and 50 out of 100 cases (50.0%) of primary non-osteogenic bone and soft tissue tumors. Of the 59 bone tumors, 37 cases (62.7%) were positive for SATB2, and of the 41 soft tissue tumors, 13 cases (31.7%) were positive for SATB2. The sensitivity of SATB2 as a diagnostic test was 92.6%, specificity 50%, positive predictive value 63.8%, and negative predictive value 87.7%.
Conclusions
Although SATB2 is a useful diagnostic marker for OSA, other clinical, histological and immunohistochemical features should be considered for the interpretation of SATB2.

Citations

Citations to this article as recorded by

Favorable treatment response to high‐grade sarcoma in neurofibromatosis 1
Michelle H. Talukder, Mauli M. Patel, Tala Al‐Saghir, Ghadir K. Katato, Janet Poulik, William J. Powell, Alysia K. Kemp, Steven Miller, Danielle Bell, Jeffrey W. Taub
Pediatric Blood & Cancer.2023;[Epub] CrossRef

Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center: Ramesh Babu Telugu, Anne Jennifer Prabhu, Nobin Babu Kalappurayil, John Mathai, Birla Roy Gnanamuthu, Marie Therese Manipadam; J Pathol Transl Med. 2017;51(3):255-263. Published online April 17, 2017; DOI: https://doi.org/10.4132/jptm.2017.01.12

10,874 View
377 Download
19 Web of Science
23 Crossref

Abstract PDF

Background
Inflammatory myofibroblastic tumor is a histopathologically distinctive neoplasm of children and young adults. According to World Health Organization (WHO) classification, inflammatory myofibroblastic tumor is an intermediate-grade tumor, with potential for recurrence and rare metastasis. There are no definite histopathologic, molecular, or cytogenetic features to predict malignant transformation, recurrence, or metastasis.
Methods
A 5-year retrospective study of histopathologically diagnosed inflammatory myofibroblastic tumors of various anatomic sites was conducted to correlate anaplastic lymphoma kinase-1 (ALK-1) expression with histological atypia, multicentric origin of tumor, recurrence, and metastasis. Clinical details of all the cases were noted from the clinical work station. Immunohistochemical stains for ALK-1 and other antibodies were performed. Statistical analysis was done using Fisher exact test.
Results
A total of 18 cases of inflammatory myofibroblastic tumors were found during the study period, of which 14 were classical. The female-male ratio was 1:1 and the mean age was 23.8 years. Histologically atypical (four cases) and multifocal tumors (three cases, multicentric in origin) were noted. Recurrence was noted in 30% of ALK-1 positive and 37.5% of ALK-1 negative cases, whereas metastasis to the lung, liver, and pelvic bone was noted in the ALK-1 positive group only.
Conclusions
Overall, ALK-1 protein was expressed in 55.6% of inflammatory myofibroblastic tumors. There was no statistically significant correlation between ALK-1 expression, tumor type, recurrence and metastasis. However, ALK-1 immunohistochemistry is a useful diagnostic aid in the appropriate clinical and histomorphologic context.

Citations

Citations to this article as recorded by

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
Mengmeng Li, Ruyue Xing, Jiuyan Huang, Chao Shi, Chunhua Wei, Huijuan Wang
Frontiers in Oncology.2023;[Epub] CrossRef
Inflammatory Myofibroblastic Tumour of the Sinonasal Tract with Orbital and Intracranial Extensions Simulating a Malignancy: A Case Report and Review of Literature
Gaveshani Mantri, Subhalaxmi Rautray, Rahul Mohanty, Vinushree Karakkandy
Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 1668. CrossRef
Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents
Aurore Pire, Daniel Orbach, Louise Galmiche, Dominique Berrebi, Sabine Irtan, Sabah Boudjemaa, Hervé J. Brisse, Laureline Berteloot, Salma Moalla, Charlotte Mussini, Pascale Philippe‐Chomette, Bogdana Tilea, Gaelle Pierron, Florent Guerin, Véronique Minar
Pediatric Blood & Cancer.2022;[Epub] CrossRef
Case Report: Early Distant Metastatic Inflammatory Myofibroblastic Tumor Harboring EML4-ALK Fusion Gene: Study of Two Typical Cases and Review of Literature
Qianqian Han, Xin He, Lijuan Cui, Yan Qiu, Yuli Li, Huijiao Chen, Hongying Zhang
Frontiers in Medicine.2022;[Epub] CrossRef
Inflammatory myofibroblastic tumor: A multi‐institutional study from the Pediatric Surgical Oncology Research Collaborative
Barrie S. Rich, Joanna Fishbein, Timothy Lautz, Nathan S. Rubalcava, Tanvi Kartal, Erika Newman, Pei En Wok, Rodrigo L. P. Romao, Richard Whitlock, Bindi Naik‐Mathuria, Stephanie F. Polites, Katrine Løfberg, Danny Lascano, Eugene Kim, Jacob Davidson, Andr
International Journal of Cancer.2022; 151(7): 1059. CrossRef
Child inflammatory myofibroblastic tumor of the kidney misdiagnosed as Wilms' tumor: case report
Yu-Feng Bai, Jing-Zhong Liu, Li-Na Yue, Li Chen, Sui-Yi Liu, Rui Liu
Radiology Case Reports.2022; 17(12): 4920. CrossRef
A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement
Vasyl Nesteryuk, Omar Hamdani, Raymond Gong, Nava Almog, Brian M. Alexander, Steffan Soosman, Ken Yoneda, Siraj M. Ali, Alexander D. Borowsky, Jonathan W. Riess
Clinical Lung Cancer.2022; 23(8): e550. CrossRef
An extremely rare case of malignant jejunal mesenteric inflammatory myofibroblastic tumor in a 61-year-old male patient: A case report and literature review
Hamdi Al Shenawi, Salamah A. Al-Shaibani, Suhair K. Al Saad, Fedaa Al-Sindi, Khalid Al-Sindi, Noor Al Shenawi, Yahya Naguib, Rami Yaghan
Frontiers in Medicine.2022;[Epub] CrossRef
Primary inflammatory myofibroblastic tumor of stomach—report of a very rare case
Ranendra Hajong, Kewithinwangbo Newme, Donkupar Khongwar
Journal of Family Medicine and Primary Care.2021; 10(1): 552. CrossRef
Complicated course of biliary inflammatory myofibroblastic tumor mimicking hilar cholangiocarcinoma: A case report and literature review
Sandra Strainiene, Kotryna Sedleckaite, Juozas Jarasunas, Ilona Savlan, Juozas Stanaitis, Ieva Stundiene, Tomas Strainys, Valentina Liakina, Jonas Valantinas
World Journal of Clinical Cases.2021; 9(21): 6155. CrossRef
Epithelioid Inflammatory Myofibroblastic Sarcoma Presenting as Gastrointestinal Bleed: Case Report and Literature Review
Alexandra Giannaki, Dimitrios Doganis, Panagiota Giamarelou, Anastasia Konidari
JPGN Reports.2021; 2(1): e019. CrossRef
Complete response to alectinib following crizotinib in an ALK-positive inflammatory myofibroblastic tumor with CNS involvement
Camila B. Xavier, Felipe S.N.A. Canedo, Fabíola A.S. Lima, Raíssa R. Melo, Luiz Guilherme C.A. Lima, José Flávio G. Marin, Ciro E. Souza, Olavo Feher
Current Problems in Cancer: Case Reports.2021; 4: 100117. CrossRef
Urinary Bladder Inflammatory Myofibroblastic Tumor With Mutated TP53 and PPFIBP1-ALK Gene Fusion
Andreia N. Barbieri, Christopher T. Tallman, Raj Satkunasivam, Joseph Annunziata, Jessica S. Thomas, Randall J. Olsen, Steven S. Shen, Michael J. Thrall, Mary R. Schwartz
AJSP: Reviews and Reports.2021; 26(1): 45. CrossRef
Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review
Malgorzata Styczewska, Agastya Patel, Joanna Jaskulowska, Jan Godzinski, Dominik Swieton, Bartosz Wasag, Juliea Dass, Ewa Bien, Malgorzata A. Krawczyk
Anti-Cancer Drugs.2021; 32(10): 1111. CrossRef
Non-squamous cell carcinoma diseases of the larynx: clinical and imaging findings
Serap Doğan, Alperen Vural, Güven Kahriman, Hakan İmamoğlu, Ümmühan Abdülrezzak, Mustafa Öztürk
Brazilian Journal of Otorhinolaryngology.2020; 86(4): 468. CrossRef
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Yan You, Li Zhang
Thoracic Cancer.2020; 11(8): 2339. CrossRef
Rare presentation of inflammatory myofibroblastic tumor in the kidney
Hiba Abduljawad, Ahmet Aslan, Khalifa Aldoseri, Erdem Yilmaz, Wael Ibrahim
Radiology Case Reports.2020; 15(8): 1266. CrossRef
Histopathological landscape of rare oesophageal neoplasms
Gianluca Businello, Carlo Alberto Dal Pozzo, Marta Sbaraglia, Luca Mastracci, Massimo Milione, Luca Saragoni, Federica Grillo, Paola Parente, Andrea Remo, Elena Bellan, Rocco Cappellesso, Gianmaria Pennelli, Mauro Michelotto, Matteo Fassan
World Journal of Gastroenterology.2020; 26(27): 3865. CrossRef
Laryngeal Inflammatory Myofibroblastic Tumor : Case Series and Literature Review
Ki-Ik Park, Sung-hoon Kim, In-Suh Park, Ji Won Kim
Journal of The Korean Society of Laryngology, Phoniatrics and Logopedics.2019; 30(1): 57. CrossRef
Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib
Qiuxia Liu, Jianguo Wei, Xizhong Liu, Jianfang Wang
Medicine.2019; 98(52): e18414. CrossRef
Inflammatory myofibroblastic tumor
Veronika Marcináková, Hana Dittrichová, Karel Franěk, Pavel Hanek
Urologie pro praxi.2019; 20(1): 40. CrossRef
Ureteral inflammatory myofibroblastic tumor
Faping Li, Hui Guo, Heping Qiu, Yuchuan Hou
Medicine.2018; 97(46): e13177. CrossRef
Pulmonary inflammatory myofibroblastic tumour misdiagnosed as a round pneumonia
Samira Naime, Anjum Bandarkar, Gustavo Nino, Geovanny Perez
BMJ Case Reports.2018; : bcr-2017-224091. CrossRef

Author index